Research programme: protein modulators - PTC Therapeutics

Drug Profile

Research programme: protein modulators - PTC Therapeutics

Alternative Names: DBMD-Utrophin; DMD Exon-51; Project Catalyst; SERCA2a protein stimulants - PTC Therapeutics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PTC Therapeutics
  • Class Small molecules
  • Mechanism of Action Dystrophin expression modulators; Insulin-like growth factor I stimulants; Myostatin inhibitors; Sarcoplasmic reticulum calcium-transporting ATPase stimulants; Utrophin activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Duchenne muscular dystrophy

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Duchenne muscular dystrophy in USA (PO)
  • 28 Jan 2014 Early research for Duchenne muscular dystrophy is ongoing in USA (PO)
  • 15 Dec 2011 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top